Ataibeckley (ATAI) Stock
Platform biotech incubating diverse mental health treatments. Here's the price, business snapshot, and what's worth knowing about Ataibeckley in October 2026.
ATAI Life Sciences NV is a clinical-stage biotechnology company focused on developing new treatments for mental health disorders. The group follows a platform approach, backing and incubating subsidiaries that advance both psychedelic-assisted and non-psychedelic therapies across indications such as depression, post-traumatic stress disorder and substance-use disorders. ATAI’s business model aims to diversify scientific risk by supporting multiple programmes rather than a single asset, and its market capitalisation (about $1.41bn) reflects investor interest in the emerging mental‑health therapeutics space. Investing in ATAI means weighing the potential of transformative clinical results against the high volatility typical of biotech: many programmes are early stage, outcomes are binary, regulatory pathways are evolving, and the company may require further capital. This is general, educational information only and not personal advice; values can rise and fall and returns are not guaranteed. Consider suitability for your goals and risk tolerance before acting.
Ataibeckley (ATAI) Stock Forecast
Analyst price target, next 12 months
$7.62
+3.6% vs today's $7.35
Price range over the last 12 months
Close to its 12-month high
Analysts covering Ataibeckley have a consensus 12-month target of $7.62, above the current price of $7.35.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 14 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding ATAIBECKLEY's stock with a target price of $7.62, indicating limited growth.
Financial Health
ATAIBECKLEY INC shows moderate revenue and cash flow, indicating steady but unremarkable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline diversity
ATAI funds multiple programmes across different mechanisms, which can spread scientific risk — though individual trials still carry binary outcomes and uncertainty.
Clinical catalysts ahead
Upcoming trial readouts and regulatory steps could materially affect the stock; these events offer potential opportunity but also volatility.
Market and regulation
Growing interest in mental-health therapeutics supports investor attention, yet regulatory change and funding needs remain key risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
